JP2007525416A - 早期活性化分子のターゲティングに基づく免疫調節 - Google Patents

早期活性化分子のターゲティングに基づく免疫調節 Download PDF

Info

Publication number
JP2007525416A
JP2007525416A JP2006503237A JP2006503237A JP2007525416A JP 2007525416 A JP2007525416 A JP 2007525416A JP 2006503237 A JP2006503237 A JP 2006503237A JP 2006503237 A JP2006503237 A JP 2006503237A JP 2007525416 A JP2007525416 A JP 2007525416A
Authority
JP
Japan
Prior art keywords
antibody molecule
early activation
aicl
disorder
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2006503237A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007525416A5 (https=
Inventor
フランシスコ サンチェスマドリッド，
カルロス マルティネス アロンソ，
デービッド サンチョ マドリッド，
パブロ エンジェル ロカモラ，
エンリック エスプルグース アルトラ，
ハビエル ベガ ラモス，
ピラル ラウツリカ ゴメス，
Original Assignee
アルボア バイオロジクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ES200300252A external-priority patent/ES2244270A1/es
Application filed by アルボア バイオロジクス， インコーポレイテッド filed Critical アルボア バイオロジクス， インコーポレイテッド
Publication of JP2007525416A publication Critical patent/JP2007525416A/ja
Publication of JP2007525416A5 publication Critical patent/JP2007525416A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
JP2006503237A 2003-01-31 2004-02-02 早期活性化分子のターゲティングに基づく免疫調節 Withdrawn JP2007525416A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES200300252A ES2244270A1 (es) 2003-01-31 2003-01-31 Nueva estrategia de regulacion inmune fundamentada en la molecula inducible durante la activacion leucocitaria cd69.
ES200302587A ES2244297A1 (es) 2003-01-31 2003-11-05 Mejoras introducidas en la patente de invencion n. 200300252 correspondiente a una nueva estrategia de regulacion inmune fundamentada en la molecula inducible durante la activacion leucocitaria cd69.
PCT/US2004/002864 WO2004069183A2 (en) 2003-01-31 2004-02-02 Immune regulation based on the targeting of early activation molecules

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2010142101A Division JP2010229156A (ja) 2003-01-31 2010-06-22 早期活性化分子のターゲティングに基づく免疫調節
JP2011100150A Division JP2011148829A (ja) 2003-01-31 2011-04-27 早期活性化分子のターゲティングに基づく免疫調節

Publications (2)

Publication Number Publication Date
JP2007525416A true JP2007525416A (ja) 2007-09-06
JP2007525416A5 JP2007525416A5 (https=) 2010-09-02

Family

ID=33553913

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006503237A Withdrawn JP2007525416A (ja) 2003-01-31 2004-02-02 早期活性化分子のターゲティングに基づく免疫調節
JP2010142101A Ceased JP2010229156A (ja) 2003-01-31 2010-06-22 早期活性化分子のターゲティングに基づく免疫調節

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010142101A Ceased JP2010229156A (ja) 2003-01-31 2010-06-22 早期活性化分子のターゲティングに基づく免疫調節

Country Status (6)

Country Link
US (3) US7867475B2 (https=)
EP (2) EP2347767A3 (https=)
JP (2) JP2007525416A (https=)
AU (2) AU2004209984B2 (https=)
CA (1) CA2513905A1 (https=)
WO (1) WO2004069183A2 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030228320A1 (en) * 2000-08-18 2003-12-11 Ashdown Martin Leonard Retroviral immunotherapy
AUPS054702A0 (en) * 2002-02-14 2002-03-07 Immunaid Pty Ltd Cancer therapy
EP2347767A3 (en) 2003-01-31 2013-06-12 Albor Biologics, Inc. Immune regulation based on the targeting of early activation molecules
EP1692516B1 (en) 2003-10-24 2010-12-01 Immunaid Pty Ltd Method of therapy
JP5386083B2 (ja) * 2004-09-08 2014-01-15 イミューンネイド ピーティーワイ リミテッド 自己免疫疾患および変性疾患を治療する方法
WO2008028501A1 (en) * 2006-09-05 2008-03-13 Eberhard-Karls-Universität Tübingen Methods for blocking the interaction between nkp80 and its ligand aicl
US20090309617A1 (en) * 2007-08-24 2009-12-17 Ye Fang Biosensor antibody functional mapping
WO2010135781A1 (en) 2009-05-27 2010-12-02 Immunaid Pty Ltd Methods of treating diseases
US20120233715A1 (en) 2009-11-17 2012-09-13 Kyowa Hakko Kirin Co., Ltd Human artificial chromosome vector
US9127052B2 (en) 2010-06-29 2015-09-08 Centre National De La Recherche Scientifique LLT-1 antibodies with new functional properties
JP5610147B2 (ja) 2010-09-15 2014-10-22 株式会社リコー クリーニングブレード、クリーニング装置、プロセスカートリッジ、及び、画像形成装置
US8440195B2 (en) 2010-11-12 2013-05-14 National University Corporation Chiba University Inhibition of CD69 for treatment of inflammatory conditions
AU2012253502C1 (en) * 2011-05-09 2017-12-14 Visen Medical, Inc. Carbonic anhydrase targeting agents and methods of using same
KR102362358B1 (ko) 2011-10-28 2022-02-15 프레닥스 에이비 치료제 및 이의 용도
EP2843051B1 (en) * 2012-04-23 2018-06-06 GeneFrontier Corporation Anti-human cd69 antibody, and use thereof for medical purposes
HUE043875T2 (hu) 2013-11-19 2019-09-30 Fredax Ab Humanizált, kallikrein-2 elleni antitest
CN120569191A (zh) 2022-11-23 2025-08-29 乔治亚大学研究基金公司 用于增加免疫应答的组合物及其使用方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4337197C1 (de) * 1993-10-30 1994-08-25 Biotest Pharma Gmbh Verfahren zur selektiven Herstellung von Hybridomazellinien, die monoklonale Antikörper mit hoher Zytotoxizität gegen humanes CD16-Antigen produzieren, sowie Herstellung bispezifischer monoklonaler Antikörper unter Verwendung derartiger monoklonaler Antikörper und des CD30-HRS-3-Antikörpers zur Therapie menschlicher Tumore
GB9422584D0 (en) 1994-02-15 1995-01-04 Medical Res Council Immunomodulation using oligosaccharides
ATE342971T1 (de) * 1997-08-15 2006-11-15 Univ Hiroshima Den zellzyklus regulierende proteine
AUPQ167599A0 (en) * 1999-07-19 1999-08-12 St. Vincent's Institute Of Medical Research Inhibitor of osteoclast precursor formation
CA2411102A1 (en) * 2000-06-20 2001-12-27 Idec Pharmaceutical Corporation Cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination
ATE427318T1 (de) * 2000-09-14 2009-04-15 Beth Israel Hospital Modulierung von il-2 und il-15 vermittelten t zellantworten
US7754208B2 (en) * 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
ES2192128B1 (es) 2001-04-27 2005-01-01 Universidad De Vigo Anticuerpo monoclonal humano que reconoce especificamente la molecula humana cd69, y su uso en terapia.
EP2347767A3 (en) 2003-01-31 2013-06-12 Albor Biologics, Inc. Immune regulation based on the targeting of early activation molecules

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
JPN6010009525, Ｓｃａｎｄｉｎａｖｉａｎ Ｊｏｕｒｎａｌ ｏｆ Ｉｍｍｕｎｏｌｏｇｙ, 2002, Ｖｏｌ．５６，Ｎｏ．４, ｐ４１７−４２８ *
JPN6010009526, Ｂｌｏｏｄ, 1996, Ｖｏｌ．８７，Ｎｏ．７, ｐ２８１５−２８２１ *
JPN6010009527, Ｊｏｕｒｎａｌ ｏｆ Ｅｘｐｅｒｉｍｅｎｔａｌ Ｍｅｄｉｃｉｎｅ, 1991, Ｖｏｌ．１７４，Ｎｏ．６, ｐ１３９３−１３９８ *
JPN6010009529, Ｅｕｒｏｐｅａｎ Ｊｏｕｒｎａｌ ｏｆ Ｉｍｍｕｎｏｌｏｇｙ, 2000, Ｖｏｌ．３０，Ｎｏ．２, ｐ６４４−６５１ *
JPN6010009531, Ｊｏｕｒｎａｌ ｏｆ Ｅｘｐｅｒｉｍｅｎｔａｌ Ｍｅｄｉｃｉｎｅ, 1994, Ｖｏｌ．１８０，Ｎｏ．５, ｐ１９９９−２００４ *

Also Published As

Publication number Publication date
JP2010229156A (ja) 2010-10-14
EP1596807A4 (en) 2008-05-21
US20110081292A1 (en) 2011-04-07
EP2347767A3 (en) 2013-06-12
US20050002929A1 (en) 2005-01-06
EP1596807A2 (en) 2005-11-23
US7867475B2 (en) 2011-01-11
US20110165071A1 (en) 2011-07-07
WO2004069183A2 (en) 2004-08-19
AU2010241228A1 (en) 2010-11-25
AU2004209984B2 (en) 2010-08-05
US8182816B2 (en) 2012-05-22
AU2010241228B2 (en) 2012-09-13
AU2004209984A1 (en) 2004-08-19
WO2004069183A3 (en) 2007-07-05
EP2347767A2 (en) 2011-07-27
CA2513905A1 (en) 2004-08-19

Similar Documents

Publication Publication Date Title
US8182816B2 (en) Methods of treating cancer
KR102714165B1 (ko) 인간 cd137에 결합하는 작동자 항체 및 이의 용도
JP4966497B2 (ja) Ｃｄ２５に対するヒトモノクローナル抗体
KR20210040827A (ko) 항 tigit 항체 및 그 용도
CA2563313C (en) Modulation of nkg2d
KR20200131272A (ko) Cd39에 결합하는 항체 및 이의 용도
US20210371537A1 (en) Anti-tnfr2 antibodies and uses thereof
KR20100014588A (ko) 길항제 ｏｘ40 항체 및 염증성 및 자가면역 질환의 치료에서의 이의 용도
KR20130098432A (ko) 치료학적 항체에 대한 조성물 및 사용 방법
CN111511766A (zh) 修饰的抗SIRPa抗体及其应用
JP2007525416A5 (https=)
US12435151B2 (en) Anti-TNFR2 antibodies and uses thereof
KR20210005007A (ko) 항-il-27 항체 및 이의 용도
JP2022545974A (ja) 抗ｃｄ４７モノクローナル抗体及びその使用
KR20230009459A (ko) 인간 ceacam1/3/5에 특이적으로 결합하는 신규 항체 및 그의 용도
KR20210013090A (ko) 당단백질 vi를 표적으로 하는 항체
JP2024522349A (ja) Ｃ－ｘ－ｃモチーフケモカイン受容体６（ｃｘｃｒ６）結合分子及びその使用方法
JP2011148829A (ja) 早期活性化分子のターゲティングに基づく免疫調節
RU2855103C1 (ru) Молекулы антитела к LILRB3 и их применение
RU2811912C2 (ru) Антитела против альфа-субъединицы ил-7r и их применение
Class et al. Patent application title: Methods Of Treating Cancer Inventors: Francisco Sanchez-Madrid (Madrid, ES) Carlos-Martinez Alonso (Madrid, ES) David Sancho Madrid (Madrid, ES) Pablo Engel Rocamora (Barcelona, ES) Enric Esplugues Artola (Barbera Del Valles, ES) Javier Vega Ramos (Barcelona, ES) Pilar Lauzurica Gómez (Barcelona, ES) Pilar Lauzurica Gómez (Barcelona, ES)

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100225

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100524

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100531

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20100622

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100823

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20101122

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20101227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110427

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20110701

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110914

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20111118